| Document |
Document Title |
|
WO/2003/024983A1 |
A transition metal complex represented by the formula (I): (I) [wherein M represents a Group 4 transition metal&semi −Y− represents (a): −C(R1)(R20)−A− (b): −C(R1)(R20)−A1(R30)−, (c): −C(R1)=A1−, or (d): −C(R1)=A1âˆ...
|
|
WO/2003/024946A2 |
The invention relates to compounds of the general formula (I), in which R, R1, R2, R3, R4 and X are as defined in claim 1. These compounds may be used in the treatment of pathologies associated with insulin resistance syndrome.
|
|
WO/2003/022801A1 |
Reverse hydroxamic acid derivatives having specific structures represented by the general formula (Ia): (Ia) (wherein A represents hydrogen, etc.&semi Ar1 represents arylene, etc.&semi Ar2 represents optionally substituted aryl, heteroar...
|
|
WO/2003/022829A1 |
The invention relates to a method for producing highly pure glycerol carbonate, whereby crude glycerol carbonate is transformed in the presence of an anhydrous base and is subsequently processed.
|
|
WO/2003/019697A2 |
The invention relates to an organic electroluminescent device which contains 2,5-diaminoterephthalic acid derivatives of formula 1a as emitter substances in one or several emitter layers in a pure or doped manner. The ring A is a triple ...
|
|
WO/2003/018542A1 |
A norstatin derivative represented by the following general formula (I) or a salt thereof, which are useful as an intermediate for medicines, e.g., HIV protease inhibitors, bestatin and taxol as carcinostatic agents, and renin inhibitors...
|
|
WO/2003/018535A2 |
The invention relates to a novel class of aminobenzophenones derivatives, to pharmaceutical preparations comprising said compounds, to dosage units of such preparations, to methods of treating patients comprising administering said compo...
|
|
WO/2003/017955A1 |
The invention concerns dyeing agents for keratinous fibers based on a developer-coupler combination, characterized in that they contain at least a 3-aminophenol derivative of formula (I) or a salt thereof, water-soluble and physiological...
|
|
WO/2003/017948A2 |
A new family of compounds, particularly aryl 1,2,3,4-tetrahydronaphthalene derivatives, is disclosed. The compounds may be used as inhibitors of P- glycoprotein-mediated transport. Use of the compounds to enhance bioavailability and to m...
|
|
WO/2003/018029A1 |
Compounds of the structure I are useful for treating bacterial growth. The compounds may be used to treat bacterial infections in human beings and to regulate biofilm formation. Pharmaceutical compositions comprising one or more such com...
|
|
WO/2003/017764A1 |
The invention relates to the use of substituted arylpropargylamines and heteroarylpropargylamines of general formula (I), optionally also in the form of an N-oxide or a salt, wherein a) R?1¿ represents an aryl or a heteroaryl which is o...
|
|
WO/2003/016265A1 |
A compound represented by the following formula, which has excellent PPAR agonistic activity: (I) wherein a, b, and c each is 0 to 4&semi R1 to R6 each represents hydrogen, hydroxy, cyano, halogeno, etc.&semi A1 and A2 each represents a ...
|
|
WO/2003/016298A2 |
The invention relates to a process for the preparation of compound(s) comprising at least one acrylate or methacrylate group, at least one linear carbonate group and at least one 5-membered cyclic carbonate group.The process comprises (A...
|
|
WO/2003/016267A1 |
The present invention relates to compounds of Formula (I) which may be useful in the treatment of diseases, such as, metabolic disorders, dyslipidemia and/or hypercholesteremia: (I).
|
|
WO/2003/014064A1 |
Naphthylurea and naphthylacetamide derivatives of formula (I) which have vanilloid receptor 1 (VR1) antagonistic activity are disclosed, formula (I) wherein Y represents formula (II) and formula (III) and the variables Q, X, R6, R7, R8, ...
|
|
WO/2003/011812A1 |
It is intended to provide a novel low−molecular weight amine derivative having a human β−tryptase inhibitory activity which shows a high absorbability, a low toxicity and an extremely high selectivity, pharmaceutically acceptable sa...
|
|
WO/2003/011799A1 |
One aspect of the present invention relates to a method for the kinetic resolution of racemic and diastereomeric mixtures of chiral compounds. The critical elements of the method are: a non-racemic chiral tertiary-amine-containing cataly...
|
|
WO/2003/011808A1 |
Are described compounds of Formula (I) in which R, R', R'', A, and D have the meanings described in the text, as useful agents in the cure of pathologies characterised by altered angiogenesis and as antitumorals.
|
|
WO/2003/011851A2 |
Compounds of formula (I) wherein A, R¿1? and R¿2? have the meanings defined in the specification, process of manufacturing these compounds and medicaments with HDAC inhibitor activity containing such a compound.
|
|
WO/2003/009850A1 |
Selected substituted piperazine compounds are effective for prophylaxis and treatment of diseases, such as obesity and the like. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, ...
|
|
WO/2003/009807A2 |
Cytoprotective compounds, many of which are phenolic derivatives characterized by a substituded phenol having certain conjugated bonds, are useful in the treatment of certain ischemic or inflammatory conditions, including but not limited...
|
|
WO/2003/010156A1 |
The invention concerns a method for preparing cyclic ketals and ketones selectively monohalogenated and more particularly chlorinated. More particularly, the invention provides a method for preparing intermediate products such as $g(a)-h...
|
|
WO/2003/007931A1 |
Drugs for potentiating the effect of cancer therapy based on the function mechanism of injuring DNA which contain compounds represented by the general formula (I) or physiologically acceptable salts thereof as the active ingredient: (I) ...
|
|
WO/2003/006453A1 |
The present invention relates to compounds of formula (I) useful in treating Alzheiner's disease and other similar diseases. These compounds include inhibitors of the betasecretase enzyme that are useful in the treatment of Alzheiner's d...
|
|
WO/2003/006420A1 |
The present invention is directed to a method of converting an aryl compound to an aniline compound, comprising the steps of (1)providing an aryl compound containing a halide group or a sulfur-containing group; (2) reacting the aryl comp...
|
|
WO/2003/006423A1 |
Disclosed are compounds of the formula (I): useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the betasecretase enzyme that are useful in the treatment of Alzeheimer's disease and ot...
|
|
WO/2003/004458A1 |
The present invention relates to 2-(benzoylamino)benzoic acid derivatives of the formula (I), wherein the variants Ar, X and R are described in the specification. The said compounds modulate the activity of peroxisome proliferator-activa...
|
|
WO/2003/005025A1 |
The present invention relates to a method for identifying compounds capable of binding the ligand binding domain of peroxisome proliferator-activated receptor gamma (PPAR$g(g)), and selectively modulating the activity of PPAR$g(g). The s...
|
|
WO/2003/004454A1 |
The invention relates to compounds of the following formula (I). In these compounds, R¿1?, R¿2?, R¿3? and R¿4? are each independently a substituted or unsubstituted cyclitol with a ring comprising six carbon atoms, or hydrogen, subst...
|
|
WO/2003/004480A2 |
A novel class of substituted piperazines and diazepanes, pharmaceutical compositions comprising them and use thereof in the treatment of diseases and disorders related to the histamine H3 receptor. More particularly, the compounds are us...
|
|
WO/2003/002547A1 |
A process for the separation of a polyol or multiple polyols in admixture with other organic compounds, usually those produced with the polyol, is described. THe process uses a distillation in a column (11) of a cyclic acetal from an aqu...
|
|
WO/2003/002255A1 |
The present invention pertains to a process for preparing a compound of Formula I that is achiral, racemic or enantiomerically enriched at the hydroxylation center indicated by comprising contacting a compound of Formula II with an oxida...
|
|
WO/2003/002519A1 |
The invention relates to novel phenol derivatives, a method for the production of said derivatives and their use in medicaments.
|
|
WO/2003/002550A1 |
The present invention relates to novel antidiabetic compounds, their derivatives, their analogs, their polymorphs and pharmaceutically acceptable compositions containing them. More particularly, the present invention relates to novel dio...
|
|
WO/2003/000641A1 |
An integrated process for the production of a dialkyl carbonate and a diol from an alkylene oxide, carbon dioxide and an aliphatic monohydric alcohol is described in which an alkylene oxide if first reacted with carbon dioxide in the pre...
|
|
WO/2003/000646A1 |
This invention relates to a series of substituted aromatic ethers of the formula (I), wherein ring A and X and Y are defined as in the specification, that exhibit activity as glycine transport inhibitors, their pharmaceutically acceptabl...
|
|
WO/2002/102765A2 |
The compound O-(2-[?18¿F]fluoroethyl)-L-tyrosine has proven to be particularly suitable for positron emission tomography and has already been tested in clinical practice. Until now, the compound has been produced according to a relative...
|
|
WO/2002/102805A1 |
The invention refers to new compounds and the use thereof as well as the use of known cyclolignans having a trans configuration of the lactone ring as inhibitors of the insulin-like growth factor-1 receptor. Said compounds can be used fo...
|
|
WO/2002/102804A1 |
The invention refers to the use of specific cyclolignans, wherein the carbon atoms in positions 9 and 9' have cis configuration, for inhibition of the insulin-like growth factor-1 receptor. Said compounds can be used for treatment of IGF...
|
|
WO/2002/102789A1 |
The present invention relates to a method of treatment and/or prophylaxis of a microbial infection, comprising the step of administering an effective amount of a compound of formula (I), in which X and Y are either the same or different ...
|
|
WO/2002/102803A1 |
The invention relates to a method for the synthesis of galanthamine, the derivatives and analogues thereof of formula (1) where R¿1? = a hydrogen atom, R¿2? = a hydroxy group, R¿1? and R¿2? together form =0, R¿3?, R¿4?, and R¿5? i...
|
|
WO/2002/100812A1 |
A medicine containing as the active ingredient a novel carboxylic acid derivative useful as an insulin resistance ameliorant. The carboxylic acid derivative is represented by the following general formula (I). Also provided are a salt or...
|
|
WO/2002/100813A2 |
Disclosed is a compound represented by Structural Formula (I): Ar is a substituted or unsubstituted aromatic group. Q is a covalent bond, -CH¿2?-or-CH¿2?CH¿2?-; W is a substituted or unsubstituted alkylene or a substituted or unsubsti...
|
|
WO/2002/100392A1 |
The present invention provides an extended release oral dosage form of prodrugs of gabapentin and other GABA analogs, which dosage forms exhibit reduced toxicity. The dosage forms are particularly useful in administering those prodrugs o...
|
|
WO/2002/100347A2 |
The present invention provides prodrugs of GABA analogs, pharmaceutical compositions of prodrugs of GABA analogs and methods for making prodrugs of GABA analogs. The present invention also provides methods for using prodrugs of GABA anal...
|
|
WO/2002/098849A2 |
Disclosed are compounds of formula X, where R¿n?, R¿20?, R¿1?, R¿2?, R¿3?, and R¿c? are defined herein. These compounds are useful in treating Alzheimer's disease and other similar diseases. Pharmaceutical compositions comprising c...
|
|
WO/2002/098851A1 |
The inventive derivatives of N,S-substitutions N'-1 [(hetero)aryl] alkyl-N'-[hetero) aryl] methyl isothioureas including bases and salts thereof with pharmacologically acceptable acids and individual optical isomers of said compositions ...
|
|
WO/2002/096864A1 |
The invention relates to carboxamide-substituted phenylurea derivatives and method for production thereof as medicaments, physiologically-acceptable salts and physiologically-functional derivatives thereof. Compounds of formula (I), in w...
|
|
WO/2002/096884A2 |
The invention relates to novel substituted benzoylketones of formula (I), in which Q = O (oxygen) or S (sulphur), R?1¿ - R?5¿ and Z have the meaning given in the description and several methods for production thereof and use thereof as...
|
|
WO/2002/096424A1 |
A method for preventing or treating epileptogenesis-associated diseases comprising the administration of a $g(b)-heterocyclic-$g(b)-aminoacid to a subject is disclosed. The disease can be for example head trauma, pain, stroke, anxiety, s...
|
